STOCK TITAN

Scholar Rock to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) announced its participation in two upcoming investor conferences. The first is the Guggenheim 4th Annual Neuro/Immunology Conference on November 15, 2022, from 2:10-2:35 p.m. ET. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, from 8:00-8:25 a.m. ET. Live webcasts can be accessed on the Scholar Rock website, with archived replays available for 90 days post-event. Scholar Rock focuses on innovative treatments for serious diseases involving protein growth factors.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

  • Guggenheim 4th Annual Neuro/Immunology Conference on Tuesday, November 15, 2022, from 2:10-2:35 p.m. ET.
  • Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, from 8:00-8:25 a.m. ET.

Live webcast of both events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentations.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts, and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Scholar Rock:

Investors

Rushmie Nofsinger

Scholar Rock

rnofsinger@scholarrock.com

ir@scholarrock.com

857-259-5573



Media

Ariane Lovell

Finn Partners

ariane.lovell@finnpartners.com

media@scholarrock.com

917-565-2204

Source: Scholar Rock

FAQ

What conferences will Scholar Rock participate in during November 2022?

Scholar Rock will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on November 15, 2022, and the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.

When is the Guggenheim Neuro/Immunology Conference for Scholar Rock?

The Guggenheim 4th Annual Neuro/Immunology Conference takes place on November 15, 2022, from 2:10-2:35 p.m. ET.

What is the date and time of the Piper Sandler Healthcare Conference for Scholar Rock?

The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, from 8:00-8:25 a.m. ET.

How can I access the live webcast of Scholar Rock's conference presentations?

The live webcast can be accessed through the Investors & Media section of the Scholar Rock website.

How long will the replay of Scholar Rock's conference webcasts be available?

The replays of the conference webcasts will be available for approximately 90 days following the presentations.

Scholar Rock Holding Corporation

NASDAQ:SRRK

SRRK Rankings

SRRK Latest News

SRRK Stock Data

4.05B
91.72M
1.07%
98.55%
16.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE